Preferred Label : glofitamab;
UNII : 06P3KLK2J8;
Origin ID : C000720108;
UMLS CUI : C5418242;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3487097/fr/columvi-glofitamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
Antineoplastic Agents, Immunological
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
glofitamab
evaluation of the transparency committee
glofitamab
---
https://www.has-sante.fr/jcms/p_3453038/fr/columvi-glofitamab-lymphome-diffus-a-grande-cellule-b
2023
false
false
false
France
French
treatment outcome
glofitamab
evaluation of the transparency committee
lymphoma, large B-Cell, diffuse
insurance, health, reimbursement
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
guidelines for drug use
adult
glofitamab
---
https://ansm.sante.fr/tableau-marr/glofitamab
2023
false
false
false
France
French
guidelines for drug use
risk management
antibodies, bispecific
antibodies, bispecific
glofitamab
glofitamab
patients guideline
Tumor Flare Reaction
signs and symptoms
continuity of patient care
Cytokine Release Syndrome
glofitamab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/columvi
2023
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
glofitamab
glofitamab
orphan drug production
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
lymphoma, large B-Cell, diffuse
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
CD3 Complex
antigens, CD20
drug approval
europe
product surveillance, postmarketing
premedication
Cytokine Release Syndrome
Drug-Related side effects and adverse reactions
pregnancy
breast feeding
drug evaluation, preclinical
glofitamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/glofitamab
2023
false
false
false
France
French
drug information
glofitamab
lymphoma, large B-Cell, diffuse
Refractory Diffuse Large B-Cell Lymphoma
glofitamab
---